Ryan Allway August 31st, 2023 News, Top News Key Findings: Pain, from various conditions, is by far the most prevalent symptom treated in clinical trials involving cannabinoids – with pain being the target condition in 46% of trials since 2010. The most commonly featured conditions in the patent landscape... Read more
Highlights: • $1.85 million in proceeds received through a strategic offering of units at $0.325 per unit with each unit comprised of one common share and one-half of one (1/2) Common Share purchase warrant exercisable at $0.50, for total potential proceeds of $3.27 million. • Financing will fuel Optimi’s... Read more
Big Data and AI Can Guide Cannabis Medicine
August 30, 2021
Robin Lefferts August 30th, 2021 App, Exclusive, News, Top Story In order for cannabis medicine to make the big leap to mainstream acceptance, a few things likely have to take place. Doctors, not just cannabis providers, need to become more comfortable discussing and prescribing the plant. Regulations need to... Read more
New CBD Trials Point the Way for Enveric, MagicMed
CBD July 30, 2021
Ryan Allway July 30th, 2021 Psychedelics, Top Story As the cannabis industry strives to gain widespread acceptance in the mainstream, scientific studies into the potential benefits of the plant and its active ingredients play a key role in reaching that goal. There are currently very few approved pharmaceutical drug... Read more
Regulatory Approvals Place Filament Health at the Forefront of Natural Psychedelic Research and Manufacturing
July 29, 2021
Ryan Allway July 29th, 2021 Psychedelics Health Canada Dealer’s License to allow the possession, production, and delivery of all controlled natural psychedelic substances VANCOUVER, BC , July 29, 2021 /CNW/ – Filament Health Corp. (NEO: FH) (“Filament” or the “Company”), a global leader in natural psychedelic drug development, has been granted an amendment to its... Read more
Wake Network Retains CRO Santé Cannabis to Conduct Clinical Trials in Psilocybin Therapies
June 16, 2021
Ryan Allway June 16th, 2021 Psychedelics TORONTO, June 16, 2021 /CNW/ – Wake Network Inc. (“Wake” or the “Company“), a global leader in psilocybin and medicinal mushroom production and developer of genomics-based integration therapies, is pleased to announce that it has entered into an agreement with Santé Cannabis (“Sante”) for consultation and... Read more
Robin Lefferts June 3rd, 2021 App, Exclusive, Top Story A sometimes overlooked aspect of the cannabis industry is the global potential for North American companies. To be sure, the United States and Canada represent the largest and most mature legal cannabis markets, and many companies are rightfully focused on... Read more
Ryan Allway May 10th, 2021 Psychedelics, Uncategorized San Diego, California–(Newsfile Corp. – May 10, 2021) – Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) (FSE: 8FW) (“Tryp”), a pharmaceutical company focused on developing clinical-stage compounds for diseases with unmet medical needs, announced today a master service agreement with Clinlogix, a Contract Research Organization (CRO),... Read more
Cybin Raises C$45 Million: The Largest Go Public Capital Raise in the Canadian Psychedelic Sector
October 22, 2020
Ryan Allway October 22nd, 2020 Psychedelics, Top Story The COMPASS Pathways Inc. (NASDAQ: CMPS) initial public offering on the NASDAQ has reinvigorated the psychedelics industry over the past couple of weeks. While COMPASS Pathways Inc. is certainly one of the largest companies in the space, there are a handful... Read more
Cardiol Therarpeutics Receives FDA Approval For Investigational New Drug (IND) Application For Phase II/III COVID-19 Trial
CBD September 25, 2020
Ryan Allway September 25th, 2020 News, Top News Trial will take place at major U.S. centers and examine the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease (CVD) Oakville, Ontario–(Newsfile Corp. – September 25, 2020) – Cardiol... Read more
